Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Solid tumors frequently metastasize to bone. This results in debilitating skeletal complications such as intractable bone pain, pathologic fractures, spinal cord compression, and hypercalcemia. Patients frequently require palliative radiation therapy or orthopedic surgery. Bisphosphonates have been shown to delay the incidence and decrease the frequency of skeletal-related events. Zoledronic acid is the only bisphosphonate that has provided benefits for patients with bone metastases secondary to a broad range of solid tumors. Among patients with metastatic breast or prostate cancer, zoledronic acid has demonstrated significant reductions in pain and skeletal morbidity compared with placebo. Zoledronic acid has also shown significant reductions in skeletal morbidity in patients with lung cancer or other solid tumors compared with placebo. Zoledronic acid is generally well tolerated. Flu-like symptoms which are manageable with standard treatment can occur. Renal monitoring is recommended, with dose reductions for patients with renal dysfunction. Osteonecrosis has been reported in patients receiving bisphosphonates and might be avoidable with appropriate dental care.

Original languageEnglish (US)
Pages (from-to)S14-S20
JournalClinical Breast Cancer
Volume7
Issue numberSUPPL. 1
DOIs
StatePublished - Jul 2007

Fingerprint

zoledronic acid
Diphosphonates
Breast Neoplasms
Neoplasm Metastasis
Safety
Bone and Bones
Placebos
Morbidity
Kidney
Intractable Pain
Neoplasms
Spontaneous Fractures
Spinal Cord Compression
Osteonecrosis
Dental Care
Hypercalcemia
Palliative Care
Orthopedics
Lung Neoplasms
Prostatic Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{a8bb15e527264cc098ec8d290b551006,
title = "Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer",
abstract = "Solid tumors frequently metastasize to bone. This results in debilitating skeletal complications such as intractable bone pain, pathologic fractures, spinal cord compression, and hypercalcemia. Patients frequently require palliative radiation therapy or orthopedic surgery. Bisphosphonates have been shown to delay the incidence and decrease the frequency of skeletal-related events. Zoledronic acid is the only bisphosphonate that has provided benefits for patients with bone metastases secondary to a broad range of solid tumors. Among patients with metastatic breast or prostate cancer, zoledronic acid has demonstrated significant reductions in pain and skeletal morbidity compared with placebo. Zoledronic acid has also shown significant reductions in skeletal morbidity in patients with lung cancer or other solid tumors compared with placebo. Zoledronic acid is generally well tolerated. Flu-like symptoms which are manageable with standard treatment can occur. Renal monitoring is recommended, with dose reductions for patients with renal dysfunction. Osteonecrosis has been reported in patients receiving bisphosphonates and might be avoidable with appropriate dental care.",
author = "Allan Lipton",
year = "2007",
month = "7",
doi = "10.3816/CBC.2007.s.002",
language = "English (US)",
volume = "7",
pages = "S14--S20",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "SUPPL. 1",

}

Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. / Lipton, Allan.

In: Clinical Breast Cancer, Vol. 7, No. SUPPL. 1, 07.2007, p. S14-S20.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer

AU - Lipton, Allan

PY - 2007/7

Y1 - 2007/7

N2 - Solid tumors frequently metastasize to bone. This results in debilitating skeletal complications such as intractable bone pain, pathologic fractures, spinal cord compression, and hypercalcemia. Patients frequently require palliative radiation therapy or orthopedic surgery. Bisphosphonates have been shown to delay the incidence and decrease the frequency of skeletal-related events. Zoledronic acid is the only bisphosphonate that has provided benefits for patients with bone metastases secondary to a broad range of solid tumors. Among patients with metastatic breast or prostate cancer, zoledronic acid has demonstrated significant reductions in pain and skeletal morbidity compared with placebo. Zoledronic acid has also shown significant reductions in skeletal morbidity in patients with lung cancer or other solid tumors compared with placebo. Zoledronic acid is generally well tolerated. Flu-like symptoms which are manageable with standard treatment can occur. Renal monitoring is recommended, with dose reductions for patients with renal dysfunction. Osteonecrosis has been reported in patients receiving bisphosphonates and might be avoidable with appropriate dental care.

AB - Solid tumors frequently metastasize to bone. This results in debilitating skeletal complications such as intractable bone pain, pathologic fractures, spinal cord compression, and hypercalcemia. Patients frequently require palliative radiation therapy or orthopedic surgery. Bisphosphonates have been shown to delay the incidence and decrease the frequency of skeletal-related events. Zoledronic acid is the only bisphosphonate that has provided benefits for patients with bone metastases secondary to a broad range of solid tumors. Among patients with metastatic breast or prostate cancer, zoledronic acid has demonstrated significant reductions in pain and skeletal morbidity compared with placebo. Zoledronic acid has also shown significant reductions in skeletal morbidity in patients with lung cancer or other solid tumors compared with placebo. Zoledronic acid is generally well tolerated. Flu-like symptoms which are manageable with standard treatment can occur. Renal monitoring is recommended, with dose reductions for patients with renal dysfunction. Osteonecrosis has been reported in patients receiving bisphosphonates and might be avoidable with appropriate dental care.

UR - http://www.scopus.com/inward/record.url?scp=34548211903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548211903&partnerID=8YFLogxK

U2 - 10.3816/CBC.2007.s.002

DO - 10.3816/CBC.2007.s.002

M3 - Article

C2 - 17683649

AN - SCOPUS:34548211903

VL - 7

SP - S14-S20

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - SUPPL. 1

ER -